Epizyme, Celgene extend partnership, add $620m in value
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Kite Readies A Second CAR-T For Filing As CD19 Competition Grows
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports